ArticleNature2022
Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed
21.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 172 citations in OpenAlex.
- Lysosomal dysfunction in neurodegenerative disease.Nature reviews. Neurology · 2026Review
- Review
- TMEM106B is a selective modulator of TDP-43 pathology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Associations between TMEM106B C-terminal fragment aggregation, age, and TDP-43 or tau pathology.Brain pathology (Zurich, Switzerland) · 2026Article
- Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.JAMA neurology · 2026Article
- Cryo-EM structures of ALECT2 filaments from human renal biopsies.Nature communications · 2026Article
- TMEM106B C-terminal fragments drive nucleocytoplasmic transport failure and TDP-43 mislocalization in the aging human brain.bioRxiv : the preprint server for biology · 2026Article
- Neurodegeneration risk variants promote lysosomal TMEM106B fibril accumulation.bioRxiv : the preprint server for biology · 2026Article
- Granulin loss and TMEM106B risk converge on lysosomal C-terminal fragment pathology in frontotemporal dementia.bioRxiv : the preprint server for biology · 2026Article
- Unraveling Alzheimer's complexity with a distinct AβNature chemical biology · 2026Article
- The amyloidogenic C-terminal region of TMEM106B modulates lipid membrane biophysical properties: Functional and pathological insights.The Journal of biological chemistry · 2026Article
- Genetic correlation analysis identifies TMEM106B, ACE, and ERC2 as genetic loci shared between Alzheimer's disease and primary psychiatric disorders.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Structure first - exploration and discovery with cryo-electron microscopy.Journal of cell science · 2026Review
- Structural basis for human RegⅢα filament formation.Communications chemistry · 2026Article
- TDP-43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models.The FEBS journal · 2026Review
- Structural insights into human signal peptide peptidase.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.bioRxiv : the preprint server for biology · 2025Article
- Genetic variation in TMEM106B alters microglial activation and cytokine responses in chronic traumatic encephalopathy.Acta neuropathologica · 2025Article
- To What Extent is Anfinsen's Thermodynamic Hypothesis Consistent With the Formation and Polymorphism of Amyloid Fibrils?Journal of molecular biology · 2025Review
- TDP-43 skein-like inclusions are formed by BAG3- and HSP70-guided co-aggregation with actin-binding proteins.Nature cell biology · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Yi Xiao Jiang *Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.
Qin Cao *Departments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.
Michael R SawayaDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0874-9043
Romany AbskharonDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.
Peng GeDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2661-8226
Michael DeTureMayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonMayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0001-7189-7917
Janine Y FuDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8854-041X
Rachel R Ogorzalek LooDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0580-2833
Joseph A LooDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-9989-1437
David S EisenbergDepartments of Chemistry and Biochemistry and Biological Chemistry, UCLA-DOE Institute, and Molecular Biology Institute, UCLA, Los Angeles, CA, USA. david@mbi.ucla.edu.ORCID http://orcid.org/0000-0003-2432-5419
Howard Hughes Medical Institute · USWinnMed · US
Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9MVascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Richard B. LIPTON · 1985 to 2026
$73.9MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5MUCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7MProject 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6MTowards Treatment of Alzheimer’s Disease by Targeting Pathogenic Tau and Beta-Amyloid StructuresR01AG070895 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVID EISENBERG · 2022 to 2026
$5.8MUV Laser for Photodissociation-Mass Spectrometry of Proteins and Protein ComplexesR01GM103479 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LOO, JOSEPH A · 2012 to 2021
$3.2MDevelopment of inhibitors and diagnostics for amyloid diseasesRF1AG048120 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2019 to 2019
$1.9MDevelopment of inhibitors for systemic amyloid diseasesR01AG048120 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2014 to 2018
$1.9MHIGH-END CRYOEM INSTRUMENT FOR UCLA ELECTRON IMAGING CTR FOR NANOMACHINES: AIDSS10RR023057 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2006 to 2006
$1.6MTowards Treatment of Alzheimer’s Disease by Targeting Pathogenic Tau and Beta-Amyloid StructuresR56AG070895 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2021 to 2021
$1.1MDirect Detection Device for atomic resolution cryoEM of macromolecular complexesS10OD018111 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2014 to 2014
$598kNCRR NIH HHS S10 RR023057NIA NIH HHS P01 AG003949NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG048120NIA NIH HHS R01 AG070895NIA NIH HHS R56 AG070895NIA NIH HHS RF1 AG048120NIA NIH HHS U19 AG063911NIGMS NIH HHS R01 GM103479NIGMS NIH HHS T32 GM007185NIH HHS S10 OD018111NINDS NIH HHS P01 NS084974
Abstract
Frontotemporal lobar degeneration (FTLD) is the third most common neurodegenerative condition after Alzheimer's and Parkinson's diseases
Indexed as
AmyloidDNA-Binding ProteinsFrontotemporal Lobar DegenerationMembrane ProteinsNerve Tissue ProteinsCryoelectron MicroscopyHumansAmyloidDNA-Binding ProteinsMembrane ProteinsNerve Tissue ProteinsTARDBP protein, humanTMEM106B protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.